April 15 (Reuters) - Neumora Therapeutics said on Monday the U.S. Food and Drug Administration had placed a clinical hold on early-stage study of its experimental schizophrenia drug. (Reporting by Sneha S K in Bengaluru; Editing by Shinjini Ganguli)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.17 USD | -1.50% | -5.17% | -46.22% |
14/05 | Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression | MT |
14/05 | Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.22% | 146.28Cr | |
+67.53% | 6.39TCr | |
-0.77% | 4.18TCr | |
+45.04% | 4.07TCr | |
-10.72% | 2.71TCr | |
+13.30% | 2.65TCr | |
-22.79% | 1.87TCr | |
+4.70% | 1.27TCr | |
+24.10% | 1.21TCr | |
+27.41% | 1.21TCr |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.
- U.S. FDA places clinical hold on Neumora's schizophrenia drug study